Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and Insertion of the selection cassette in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-MKNK1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Mitogen-activated protein kinase-interacting serine/threonine-protein kinase 1 (MNK1) also known as MAP kinase-interacting kinase 1 is an enzyme with a molecular weight of approximately 51 kDa. MNK1 plays an important role in the regulation of protein synthesis by phosphorylating eukaryotic initiation factor 4E (eIF4E). Researchers find high expression of MNK1 in many tissues especially within the brain and immune system which suggests its involvement in diverse cellular processes.
Biological function summary
The protein kinase MNK1 regulates the translation of mRNA by forming part of the signaling complex that includes eIF4E. This complex plays a role in stress response cell growth and the immune response. Protein synthesis regulated by MNK1 affects cellular activities by selectively translating specific mRNAs related to those processes. MNK1's specific regulation often depends on signals received through upstream kinases.
Pathways
MNK1 is a part of the mitogen-activated protein kinase (MAPK) signaling cascade particularly the extracellular signal-regulated kinase (ERK) and p38 MAPK pathways. These pathways find involvement in transmitting signals from the cell membrane to the nucleus affecting gene expression and cellular responses. MNK1 modulates its activity in response to signals from upstream proteins such as ERK1/2 or p38α/β which are likely to influence the regulation of eIF4E and therefore translation initiation.
Scientists observe MNK1 implications in cancer progression and neurodegenerative diseases. MNK1-mediated phosphorylation of proteins like eIF4E and its overactivation often correlates with tumor growth and resistance to chemotherapy. Additionally research links MNK1's altered activity to neurodegenerative conditions such as Alzheimer's disease. Interactions between MNK1 and other proteins like eIF4E suggest potential roles for MNK1 in these disease pathologies making it an attractive target for therapeutic interventions.
